Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| SGMO | SANGAMO THERAPEUTICS, INC | 2026-04-02 18:57:26 | 0.29 | -0.01 | -2.4 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGMO | 0001001233 | SANGAMO THERAPEUTICS, INC | US8006771062 | 2549006WMRKRC4G32Z67 | 680359556 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 501 CANAL BLVD. | RICHMOND | CA | 94084 | UNITED STATES | US | 5109706000 | 501 CANAL BLVD., RICHMOND, CA, 94084 | 501 CANAL BLVD., RICHMOND, CA, 94084 | SANGAMO BIOSCIENCES INC | Biotechnology | 1995 | Sandy Macrae | 354 | http://sangamo.com | 152,669,558 | 350,688,142 | 414,274,017 | Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases. | 2026-04-02 19:22:35 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 152,669,558 | 78,423,403 | 105.6262 | 414,274,017 | 189,563,998 | 84.3594 |
| 2024 | 74,246,155 | -154,807,921 | -67.5858 | 224,710,019 | 45,803,669 | 25.602 |
| 2023 | 229,054,076 | -403,866,677 | -63.81 | 178,906,350 | 10,423,033 | 6.1864 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Prathyusha Duraibabu | Chief Financial Officer | 2024 | 483,960 | 0 | 323,974 | 371,681 | 6,430 | 1,186,045 |
| Nathalie Dubois-Stringfellow | Chief Development Officer | 2024 | 453,600 | 0 | 323,974 | 348,365 | 6,430 | 1,132,369 |
| Alexander D. Macrae | Chief Executive Officer | 2024 | 716,366 | 0 | 909,400 | 825,254 | 6,430 | 2,457,450 |
| Jason D. Fontenot | Chief Scientific Officer, Senior Vice President | 2023 | 512,179 | 0 | 113,715 | 0 | 6,300 | 972,242 |
| Prathyusha Duraibabu | Chief Financial Officer, Senior Vice President | 2023 | 483,960 | 0 | 142,145 | 0 | 6,300 | 1,057,465 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 142 |
| 2024 | 183 |
| 2023 | 405 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 39,552,000 | 57,800,000 | 176,232,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 112,670,000 | 111,521,000 | 234,057,000 |
| General And Administrative Expenses | 34,886,000 | 44,727,000 | 61,167,000 |
| Operating Expenses | 160,791,000 | 161,769,000 | 450,237,000 |
| Operating Income | -121,239,000 | -103,969,000 | -274,005,000 |
| Net Income | -122,932,000 | -97,941,000 | -257,831,000 |
| Earnings Per Share Basic | -0.44 | -0.49 | -1.48 |
| Earnings Per Share Diluted | -0.44 | -0.49 | -1.48 |
| Weighted Average Shares Outstanding Basic | 280,193,000 | 201,699,000 | 174,444,000 |
| Weighted Average Shares Outstanding Diluted | 280,193,000 | 201,699,000 | 174,444,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 20,948,000 | 41,918,000 | 45,204,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 371,000 | 526,000 | 923,000 |
| Inventories | — | — | — |
| Non Trade Receivables | 10,142,000 | 4,072,000 | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 35,830,000 | 51,691,000 | 94,328,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 11,042,000 | 17,887,000 | 26,874,000 |
| Other Assets Non Current | 871,000 | 879,000 | 16,627,000 |
| Total Assets Non Current | 23,915,000 | 49,944,000 | 70,992,000 |
| Total Assets | 59,745,000 | 101,635,000 | 165,320,000 |
| Accounts Payable | 14,437,000 | 15,485,000 | 15,259,000 |
| Deferred Revenue | 899,000 | 7,556,000 | 0 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 9,409,000 | 8,195,000 | 23,554,000 |
| Total Liabilities Current | 42,466,000 | 45,805,000 | 47,731,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 580,000 | 933,000 | 1,187,000 |
| Total Liabilities Non Current | 31,547,000 | 33,060,000 | 34,702,000 |
| Total Liabilities | 74,013,000 | 78,865,000 | 82,433,000 |
| Common Stock | 3,507,000 | 2,128,000 | 1,781,000 |
| Retained Earnings | -1,627,249,000 | -1,504,317,000 | -1,406,376,000 |
| Accumulated Other Comprehensive Income | -1,464,000 | -7,530,000 | -4,595,000 |
| Total Shareholders Equity | -14,268,000 | 22,770,000 | 82,887,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 3,961,000 | 5,107,000 | 15,065,000 |
| Share Based Compensation Expense | 9,079,000 | 12,382,000 | 27,363,000 |
| Other Non Cash Income Expense | -32,000 | -330,000 | -1,119,000 |
| Change In Accounts Receivable | -155,000 | -397,000 | -2,755,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | 0 | -556,000 | -392,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,794,000 | -14,169,000 | 5,589,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -97,208,000 | -67,139,000 | -224,842,000 |
| Purchases Of Marketable Securities | — | 0 | 59,551,000 |
| Sales Of Marketable Securities | 0 | 34,730,000 | — |
| Acquisition Of Property Plant And Equipment | 102,000 | 267,000 | 21,155,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -102,000 | 37,524,000 | 153,531,000 |
| Tax Withholding For Share Based Compensation | 3,263,000 | 904,000 | 1,453,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 21,483,000 | 7,132,000 | 15,106,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | 0 |
| Cash From Financing Activities | 70,749,000 | 28,377,000 | 14,588,000 |
| Change In Cash | -22,470,000 | -3,286,000 | -55,240,000 |
| Cash At End Of Period | 20,948,000 | 41,918,000 | 45,204,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.44 | -0.49 | -1.48 |
| Price To Earnings Ratio | -0.9545 | -2.0816 | -0.3671 |
| Earnings Growth Rate | -10.2041 | -66.8919 | 18.4 |
| Price Earnings To Growth Ratio | 0.0935 | 0.0311 | -0.02 |
| Book Value Per Share | -0.0509 | 0.1129 | 0.4751 |
| Price To Book Ratio | -8.2479 | 9.0353 | 1.1434 |
| Ebitda | -118,971,000 | -92,834,000 | -242,766,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -2,884,000 | -3,880,000 | -21,592,000 |
| Free Cash Flow | -94,324,000 | -63,259,000 | -203,250,000 |
| Return On Equity | 8.6159 | -4.3013 | -3.1106 |
| One Year Beta | 1.2644 | 2.3764 | 1.5432 |
| Three Year Beta | 1.569 | 1.7719 | 1.5899 |
| Five Year Beta | 1.5912 | 1.3264 | 1.3012 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | 2026-04-01 | 800,000 | A | 800,000 |
| Macrae Sandy | Director, PRESIDENT, CEO AND DIRECTOR | 2026-04-01 | 2,500,000 | A | 2,500,000 |
| Davis Gregory D | Head of Research & Technology | 2026-04-01 | 225,000 | A | 225,000 |
| Jain Nikunj | Principal Accounting Officer | 2026-04-01 | 225,000 | A | 225,000 |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | 2026-04-01 | 800,000 | A | 800,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 80,071 | 190,645 | 0.42 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 1,218 | 2,900 | 0.42 |
| Virtu Financial LLC | 2025-12-31 | 56,000 | 132,356 | 0.4231 |
| Invesco Ltd. | 2025-12-31 | 420,123 | 1,000,292 | 0.42 |
| ORACLE INVESTMENT MANAGEMENT INC | 2025-12-31 | 435,012 | 1,035,742 | 0.42 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 868,134 | 464,885.76 | 0.0174 |
| VICTORY PORTFOLIOS III | 2026-01-31 | Victory Extended Market Index Fund | USMIX | 34,680 | 18,571.14 | 0.0024 |
| RUSSELL INVESTMENT CO | 2026-01-31 | Class M | RUNTX | 888 | 475.52 | 0.0001 |
| RUSSELL INVESTMENT CO | 2026-01-31 | Class R6 | RSCRX | 888 | 475.52 | 0.0001 |
| RUSSELL INVESTMENT CO | 2026-01-31 | Class S | RLESX | 888 | 475.52 | 0.0001 |